Checkmate Pharmaceuticals, Inc. announced the appointment of Alan Bash as President, effective March 1, 2022. Mr. Bash, who will also join the Board of Directors, will succeed Alan Fuhrman, who has served as interim President and Chief Executive Officer since October 2021. Mr. Bash will serve as a Class I director of the Board for a term expiring on the date of the Company's annual meeting of stockholders to be held in 2024, or until his earlier death, resignation or removal.

Mr. Bash, age 50, has served in various roles of increasing responsibility at Bristol Myers Squibb (“BMS”) over the last 22 years. He is currently Senior Vice President, Commercial Model Innovation, at BMS. Mr. Fuhrman will continue to serve Checkmate as a member of the Board of Directors. Mr. Bash's appointment follows the recent additions of Jon Wigginton, M.D. and Joy Yan, M.D., Ph.D. to the Checkmate Board of Directors.

These appointments provide complementary leadership and immuno-oncology expertise and position Checkmate well to advance the development of vidutolimod and unlock its value potential.